Mirae Asset Healthcare Fund Direct Growth
Mirae Asset Investment Managers (India) Private Limited · Direct Plan · Growth
Fund overview
1% on or before 30D, NIL after 30D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹6,053 | +1,053 |
| 3 Years | ₹5,000 | ₹8,870 | +3,870 |
| 5 Years | ₹5,000 | ₹12,997 | +7,997 |
Calculated using the fund's annualised return since inception (21.1% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
30 securitiesTop 10 holdings make up 55.0% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 10.15% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 9.79% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 6.80% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 5.62% |
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.51% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.84% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.78% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.78% |
| Alkem Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.76% |
| Ipca Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.39% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹3,494 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹3,494 Cr
Exit load, stamp duty & tax
02-Jul-18
1% on or before 30D, NIL after 30D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 16.10% |
| Beta | 0.99 |
| Sharpe Ratio | 2.42 |
| Sortino Ratio | -0.33 |
| Treynor Ratio | 0.39 |
| Jensen's Alpha | -2.80 |
| Information Ratio | -0.37 |
| R-Squared | 97.95% |
| Max Drawdown | -4.84% |
| Upside Capture | 95.47% |
| Downside Capture | 113.47% |
Fund management
Scheme Details
Investment objective
The Investment Objective Of The Scheme Is To Seek To Generate Long Term Capital Appreciation Through Investing In Equity And Equity Related Securities Of Companies Benefitting Directly Or Indirectly In Healthcare And Allied Sectors In India. The Scheme Does Not Guarantee Or Assure Any Returns.
Fund house
Mirae Asset Investment Managers (India) Private Limited
Frequently asked questions
What is the NAV of Mirae Asset Healthcare Fund Direct Growth?
The NAV of Mirae Asset Healthcare Fund Direct Growth is ₹48.90 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by Mirae Asset Healthcare Fund Direct Growth?
The expense ratio charged by Mirae Asset Healthcare Fund Direct Growth is 0.62%.
What is the Min. SIP of Mirae Asset Healthcare Fund Direct Growth?
The minimum SIP investment in Mirae Asset Healthcare Fund Direct Growth is ₹99 per month.
What is the Min. Lumpsum of Mirae Asset Healthcare Fund Direct Growth?
The minimum lumpsum investment in Mirae Asset Healthcare Fund Direct Growth is ₹5,000.
What is the Exit Load of Mirae Asset Healthcare Fund Direct Growth?
The exit load for Mirae Asset Healthcare Fund Direct Growth is: 1% on or before 30D, NIL after 30D
.svg){kind=small}